OncoResponse's Series A - IV Round

OncoResponse raised a round of funding on March 09, 2017. Investors include HT Family Office.

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded…

Articles about OncoResponse's Series A - IV Round: